Name: Capital Market Publishers India Pvt. Ltd.
Telephone: 91-22-25229720

LOGIN HERE

Cancel

BSE Code : 524500 | NSE Symbol : KILITCH | ISIN : INE729D01010 | Industry : Pharmaceuticals - Indian - Formulations |

Board Meeting

Announcement Date	Date Of Meeting	Purpose	Detail
13-May-2025	19-May-2025	Quarterly Results	Kilitch Drugs India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 19/05/2025 inter alia to consider and approve Audited Standalone and Consolidated Financial Results for the quarter ended 31st March 2025 Outcome of Board Meeting (As Per BSE Announcement Dated on: 19/05/2025)
03-Feb-2025	11-Feb-2025	Quarterly Results	KILITCH DRUGS (INDIA) LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/02/2025 inter alia to consider and approve unaudited standalone and consolidated financial results for the quarter ended 31st December 2024 Considered and Approved unaudited financial results for quarter ending 31st December, 2024 (As per BSE Announcement Dated on 11/02/2025)
04-Nov-2024	12-Nov-2024	Quarterly Results	KILITCH DRUGS (INDIA) LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/11/2024 inter alia to consider and approve unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter ended 30th September 2024. We are submitting herewith the financial results for the quarter ended 30th September, 2024 (As Per BSE Announcement Dated on: 12/11/2024)
30-Aug-2024	30-Aug-2024	Change in Auditors	Pursuant to Regulation 30 of SEBI LODR Regulations, this is to inform you that the Board of Directors approved the appointment of M/s C Sharat & Company, Chartered Accountants as a Statutory Auditors of the Company
26-Aug-2024	26-Aug-2024	Change in Auditors	Appointment of M/s. AVHP & Company LLP, Chartered Accountant (FRN:W100671) as Statutory Auditors of the Company
01-Aug-2024	08-Aug-2024	Quarterly Results	KILITCH DRUGS (INDIA) LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/08/2024 inter alia to consider and approve unaudited financial results for the period ended 30th June 2024 Submission of Quarterly Standalone and Financial Results for the quarter ended 30th June 2024 (As Per BSE Announcement Dated on: 08/08/2024)
20-May-2024	27-May-2024	Quarterly Results	KILITCH DRUGS (INDIA) LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/05/2024 inter alia to consider and approve financial results for the quarter and year ended 31st March 2024 Financial Results for the year ended 31st March, 2024 Quarterly financial results for the year ended 31st March, 2024 (As Per BSE Announcement Dated on 27.05.2024)
31-Jan-2024	08-Feb-2024	Quarterly Results	KILITCH DRUGS (INDIA) LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/02/2024 inter alia to consider and approve the unaudited standalone and consolidated financial results for the quarter ended 31st December 2023 Declaration of Financial Results for the quarter ended 31st December, 2023 Submission of financial results for the quarter ended 31st December, 2023 (As Per BSE Announcement dated on 08.02.2024)
01-Nov-2023	09-Nov-2023	Quarterly Results	KILITCH DRUGS (INDIA) LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/11/2023 inter alia to consider and approve and consider the unaudited Financial Results (Standalone and Consolidated) of the Company for the half year ended 30th September 2023. Enclosed please find Financial Results for the quarter ended 30th September, 2023 (As Per BSE Announcement dated on 09.11.2023)
04-Aug-2023	11-Aug-2023	Quarterly Results	KILITCH DRUGS (INDIA) LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/08/2023 inter alia to consider and approve Pursuant to Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 as amended this is to inform you that the meeting of the Board of Directors of the Company will be held on Friday 11th August 2023 inter-alia to consider and approve the unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter ended 30th June 2023. Considered and approved financial results for the quarter ended 30th June, 2023 Details of the agenda approved at the meeting is enclosed herewith (As Per BSE Announcement Dated on 11.08.2023)
29-Jul-2023	29-Jul-2023	Others	Pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015, this is to inform you that the Board of Directors of the Company at its meeting held today i.e. Saturday, 29th July, 2023 considered and approved obtaining credit facilities from bank, in aggregate, not exceeding Rs. 100 crore for the purpose of meeting fund requirements of the company.
19-Jul-2023	22-Jul-2023	Conversion	KILITCH DRUGS (INDIA) LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 22/07/2023 inter alia to consider and approve To consider and approve conversion of warrants into the equity shares of the Company to the specified person only Pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015, this is to inform you that the Board of Directors of the Company at its meeting held today i.e. Saturday, 22nd July, 2023 considered and approved the following; Obtaining credit facilities from bank not exceeding Rs. 50,50,00,000 for the purpose of meeting day to day fund requirements of the Company. Conversion of 5,00,000 convertible warrants into 5,00,000 equity shares of face value of Rs. 10/- each of the Company out of the warrants allotted on 24th January, 2023 on preferential allotment basis to the allottees pursuant to exercise of their rights of conversion of warrants into equity shares and accordingly the Board of Directors have allotted 5,00,000 equity shares of face value of Rs. 10 each fully paid up on account of conversion (As Per BSE Announcement Dated on 22/07/2023)
17-May-2023	29-May-2023	Accounts	KILITCH DRUGS (INDIA) LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2023 inter alia to consider and approve Pursuant to Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 as amended this is to inform you that the meeting of the Board of Directors of the Company will be held on Monday 29th May 2023 inter-alia to consider and approve the audited Financial Results (Standalone and Consolidated) of the Company for the quarter and year ended 31st March 2023 Pursuant to Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015,we hereby would like to inform you that Board of Directors of the Company, at its meeting held today i.e. 29th May, 2023 have considered and approved the following; 1. Audited Financial Results (Standalone and Consolidated) for the quarter and year ended 31st March, 2023. The copy of Audited Financial Results (Standalone and Consolidated) as adopted and approved by the Board of Directors and Auditor''s report thereon are attached herewith for your ready reference. 2. Pursuant to Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby declare that the Statutory Auditors of the Company have issued their audit reports with unmodified (i.e., unqualified) opinion on the Financial Statements (Standalone and Consolidated) for the year ended on 31st March, 2023. Pursuant to Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015,we hereby would like to inform you that Board of Directors of the Company, at its meeting held today i.e. 29th May, 2023 have considered and approved the following; 1. Audited Financial Results (Standalone and Consolidated) for the quarter and year ended 31st March, 2023. The copy of Audited Financial Results (Standalone and Consolidated) as adopted and approved by the Board of Directors and Auditor''s report thereon are attached herewith for your ready reference. 2. Pursuant to Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby declare that the Statutory Auditors of the Company have issued their audit reports with unmodified (i.e., unqualified) opinion on the Financial Statements (Standalone and Consolidated) for the year ended on 31st March, 2023. (As Per BSE Announcement Dated on 29.05.2023) This has a reference to the outcome of board meeting dated 29th May, 2023 wherein the Board considered and approved the Audited Financial Results (Standalone and Consolidated) for the quarter and year ended 31st March, 2023. Post submission of the said outcome to the stock exchanges, an inadvertent error was notice in the amount in consolidated statement of Cash Flow under the head 'Capital expenditure on PPE, CWIP including capital advances' was not captured properly due to link issue. The revised Consolidated Audited Financial Results for the quarter and year ended 31st March, 2023 is attached herewith. All other particulars and details remain unchanged. The corrigendum shall be read with the Outcome of Board meeting dated 29th May, 2023. (As Per BSE Announcement Dated on 31.05.2023)
15-Mar-2023	15-Mar-2023	Change in Directors	Disclosure pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
03-Feb-2023	14-Feb-2023	Quarterly Results	KILITCH DRUGS (INDIA) LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2023 inter alia to consider and approve Pursuant to Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 as amended this is to inform you that the Meeting of the Board of Directors of the Company will be held on Tuesday 14th February 2023 inter-alia to consider and approve the Standalone and Consolidated un-audited Financial Results of the Company for the quarter ended 31st December 2022. Financial Results for the quarter ended 31st December, 2022 Approval of quarterly results and reappointment of independent director (As Per BSE Announcement Dated on 14.02.2023)

1 2 3

LOGIN HERE

Kilitch Drugs (India) Ltd

Board Meeting